Sarepta Surges on Optimism Over Muscular Dystrophy Drug
This article is for subscribers only.
Sarepta Therapeutics Inc., a drug developer with no products on the market, rose to its highest value in five months after saying it plans to submit its Duchenne muscular dystrophy treatment for approval this year.
Sarepta increased 39 percent to $33.98 at 4 p.m. New York time, its highest closing price since Nov. 11.